Excitatory neurotransmission at many CNS synapses depends upon AMPA-type glutamate receptors. Derangements in AMPA receptor-mediated synaptic transmission may be a contributing factor in neurological and neurodegenerative diseases and could be a target for therapeutic intervention. Drugs that positively modulate AMPA receptors by reducing AMPA receptor desensitization and/or slowing AMPA receptor deactivation, such as thiazide derivatives (cyclothiazide, diazoxide, IDRA 21) and benzoylpiperidine derivatives (1-BCP, CX516, aniracetam), facilitate AMPA receptor-mediated processes and may have beneficial therapeutic effects. For example, AMPA modulators facilitate long-term potentiation, which may be important for memory storage, and facilitate memory encoding in behavioral experiments. Thus, AMPA modulators might ameliorate memory deficits that occur in dementia, such as Alzheimer's disease. However, AMPA receptor-mediated excitotoxicity may occur with excessive AMPA receptor activation such as in seizures or ischemia, and positive AMPA modulators would promote neuronal injury under those conditions. Regardless of the ultimate clinical utility of positive AMPA modulators, their discovery and study have already provided significant insight into the physiology and structural determinants of important AMPA receptor properties. This review attempts to synthesize a variety of studies that have utilized these AMPA modulators to gain insight into fundamental as well as clinically relevant AMPA receptor-mediated processes.
INTRODUCTION
The hippocampus is an important structure for normal memory function, and it is also a structure vulnerable to neurodegenerative pathology as well as acquired injury. For example, in Alzheimer's disease neuritic plaques and neurofibrillary tangles are often found in the hippocampus, and the prominent symptoms of such patients are cognitive impairment and memory deficiencies. When the brain is subjected to global ischemia or prolonged seizures, the CA1 pyramidal neurons in the hippocampus are selectively vulnerable to damage. Long-term potentiation (LTP) and glutamate excitotoxicity are two experimental phenomena observed in the hippocampus. They have in common dependence upon excitatory synaptic transmission mediated by AMPA-type glutamate receptors. Therefore, drugs that positively modulate AMPA receptors could potentially facilitate both types of AMPA receptor-mediated processes. Because LTP is considered a cellular mechanism possibly required for memory and learning, pharmacologically facilitating LTP would be a treatment strategy for improving memory or overcoming memory deficits that occur in dementing diseases. In contrast, AMPA receptormediated excitotoxicity could be an undesirable drawback of using positive AMPA modulators for ''cognitive enhancement'' therapy.
This review focuses upon the pharmacology and physiological actions of two classes of positive AMPA receptor modulators (Fig. 1) , thiazide derivatives (cyclothiazide, diazoxide, and IDRA 21) and benzoylpi-
